Intan Dewi and Frank van de Veerdonk, theme Infectious diseases and global health, published in Cell Reports Medicine that Neuraminidase and SIGLEC15 modulate the host defense against pulmonary aspergillosis. Influenza-associated pulmonary aspergillosis (IAPA) has been reported increasingly since the advent of use of neuraminidase (NA) inhibitors following the 2009 influenza pandemic.
The researchers hypothesize that blocking host NA modulates the immune response against Aspergillus fumigatus. They demonstrate that NA influences the host response against A. fumigatus in vitro and that oseltamivir increases the susceptibility of mice to pulmonary aspergillosis. Oseltamivir impairs the mouse splenocyte and human peripheral blood mononuclear cell (PBMC) killing capacity of A. fumigatus, and adding NA restores this defect in PBMCs. Furthermore, the sialic acid-binding receptor SIGLEC15 is upregulated in PBMCs stimulated with A. fumigatus. Silencing of SIGLEC15 decrease PBMC killing of A. fumigatus.
They provide evidence that host NA activity and sialic acid recognition are important for anti-Aspergillus defense. NA inhibitors might predispose individuals with severe influenza to invasive aspergillosis. These data shed light on the pathogenesis of invasive fungal infections and may identify potential therapeutic targets.
Related news items
Neolithic made us taller and more intelligent, but more prone to heart disease How modern European populations have evolved over the past 50,000 years6 April 2022
After the Neolithic, European populations showed an increase in height and intelligence, reduced skin pigmentation and increased risk of cardiovascular disease due to genetic changes that lowered concentrations of 'good' HDL cholesterol.read more
Immunogenetic studies in diverse populations are essential Clear immunological differences between populations in Europe and Africa15 February 2022
Genetic factors that partly determine host defenses sometimes differ significantly between people and populations. This is shown in a publication in the American Journal of Human Genetics by researchers from the Netherlands, Tanzania and India.read more
What does the shingles vaccine teach us about other vaccines? Investigating the role of trained immunity27 January 2022
The vaccine for shingles, a condition that causes itching, pain, and blisters, is 90% effective, even in elderly. This is remarkable, since most vaccines offer less protection in elderly. Radboudumc is investigating why this vaccine works so well and how it might help us to develop better vaccines.read more